Log in
NASDAQ:SEEL

Seelos Therapeutics Stock Forecast, Price & News

$0.61
0.00 (0.00 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.56
Now: $0.61
$0.64
50-Day Range
$0.60
MA: $0.85
$1.13
52-Week Range
$0.42
Now: $0.61
$1.71
Volume849,615 shs
Average Volume1.17 million shs
Market Capitalization$27.18 million
P/E RatioN/A
Dividend YieldN/A
Beta2.02
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. The company was founded in 2016 and is based in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SEEL
CUSIPN/A
CIKN/A
Phone646-293-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$380,000.00

Profitability

Net Income$-51,260,000.00

Miscellaneous

EmployeesN/A
Market Cap$27.18 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$0.61
0.00 (0.00 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SEEL News and Ratings via Email

Sign-up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions

How has Seelos Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Seelos Therapeutics' stock was trading at $0.78 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SEEL stock has decreased by 21.5% and is now trading at $0.6120.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Seelos Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Seelos Therapeutics
.

When is Seelos Therapeutics' next earnings date?

Seelos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Seelos Therapeutics
.

What price target have analysts set for SEEL?

3 brokers have issued 1-year target prices for Seelos Therapeutics' stock. Their forecasts range from $4.00 to $12.00. On average, they anticipate Seelos Therapeutics' stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 989.3% from the stock's current price.
View analysts' price targets for Seelos Therapeutics
.

Are investors shorting Seelos Therapeutics?

Seelos Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 421,300 shares, an increase of 121.7% from the August 15th total of 190,000 shares. Based on an average trading volume of 1,300,000 shares, the days-to-cover ratio is presently 0.3 days.
View Seelos Therapeutics' Short Interest
.

Who are some of Seelos Therapeutics' key competitors?

What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Onconova Therapeutics (ONTX), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Heat Biologics (HTBX), Ibio (IBIO), Opko Health (OPK) and SCYNEXIS (SCYX).

Who are Seelos Therapeutics' key executives?

Seelos Therapeutics' management team includes the following people:
  • Dr. Raj Mehra Ph.D., Chairman, CEO, Pres & Interim CFO (Age 59)

What is Seelos Therapeutics' stock symbol?

Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."

Who are Seelos Therapeutics' major shareholders?

Seelos Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Uniplan Investment Counsel Inc. (3.02%), Tocqueville Asset Management L.P. (0.40%) and Virtu Financial LLC (0.21%).
View institutional ownership trends for Seelos Therapeutics
.

Which institutional investors are selling Seelos Therapeutics stock?

SEEL stock was sold by a variety of institutional investors in the last quarter, including Uniplan Investment Counsel Inc., and Tocqueville Asset Management L.P..
View insider buying and selling activity for Seelos Therapeutics
.

Which institutional investors are buying Seelos Therapeutics stock?

SEEL stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for Seelos Therapeutics
.

How do I buy shares of Seelos Therapeutics?

Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Seelos Therapeutics' stock price today?

One share of SEEL stock can currently be purchased for approximately $0.61.

How big of a company is Seelos Therapeutics?

Seelos Therapeutics has a market capitalization of $27.18 million and generates $380,000.00 in revenue each year.

What is Seelos Therapeutics' official website?

The official website for Seelos Therapeutics is www.seelostherapeutics.com.

How can I contact Seelos Therapeutics?

Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at 646-293-2100 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.